Treatment with tolebrutinib led to greater confirmed disability improvement at 6 months compared with placebo in patients ...

No added benefits in slowing MS disability progression were found in a study that increased Ocrevus dosing to 2-3 times the ...

Hauser frets that amid federal cutbacks, young scientists may turn away from medical research, knee-capping health care ...

A significant benefit was observed with Tysabri over Rebif in delaying SPMS disability progression when therapeutic lag was ...

Researchers found that higher ocrelizumab exposure over 10 years was associated with less risk of disability progression in ...

Jan. 9, 2024 — A combination of only 11 proteins can predict long-term disability outcomes in multiple sclerosis (MS) for different individuals. The identified proteins could be used to tailor ...

Roche Holdings AG (OTC:RHHBY) on Wednesday announced data from MUSETTE Phase 3 trial of a high dose of Ocrevus (ocrelizumab) ...

Roche’s phase III MUSETTE trial of Ocrevus high dose in people with relapsing multiple sclerosis fails to meet primary endpoint: Basel Friday, April 4, 2025, 11:00 Hrs [IST] Roc ...

Tolebrutinib regulatory submission accepted for priority review in the US for patients with multiple sclerosisIf approved, tolebrutinib would be ...

“These findings reaffirm that the current Ocrevus IV 600 mg is optimally dosed to significantly slow disability progression,” ...

Jan. 9, 2024 — A combination of only 11 proteins can predict long-term disability outcomes in multiple sclerosis (MS) for different individuals. The identified proteins could be used to tailor ...